AllianceBernstein’s Haemonetics HAE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$7.38M Buy
92,135
+465
+0.5% +$30.3K ﹤0.01% 1358
2025
Q4
$7.35M Sell
91,670
-3,271
-3% -$220K ﹤0.01% 1367
2025
Q3
$4.63M Sell
94,941
-2,797
-3% -$173K ﹤0.01% 1552
2025
Q2
$7.29M Sell
97,738
-1,261
-1% -$83.5K ﹤0.01% 1323
2025
Q1
$6.29M Sell
98,999
-782
-0.8% -$53.2K ﹤0.01% 1363
2024
Q4
$7.79M Sell
99,781
-8,564
-8% -$688K ﹤0.01% 1292
2024
Q3
$8.71M Sell
108,345
-1,396
-1% -$113K ﹤0.01% 1261
2024
Q2
$9.08M Buy
109,741
+91
+0.1% +$8.01K ﹤0.01% 1212
2024
Q1
$9.36M Sell
109,650
-1,281
-1% -$101K ﹤0.01% 1186
2023
Q4
$9.49M Sell
110,931
-1,571
-1% -$136K ﹤0.01% 1186
2023
Q3
$10.1M Sell
112,502
-14,883
-12% -$1.33M ﹤0.01% 1086
2023
Q2
$10.8M Buy
127,385
+11,018
+9% +$932K ﹤0.01% 1084
2023
Q1
$9.63M Sell
116,367
-1,312
-1% -$106K ﹤0.01% 1109
2022
Q4
$9.26M Sell
117,679
-179
-0.2% -$14.4K ﹤0.01% 1131
2022
Q3
$8.72M Sell
117,858
-609
-0.5% -$43.7K ﹤0.01% 1154
2022
Q2
$7.72M Buy
118,467
+719
+0.6% +$42.6K ﹤0.01% 1235
2022
Q1
$7.44M Sell
117,748
-226
-0.2% -$12.3K ﹤0.01% 1393
2021
Q4
$6.26M Sell
117,974
-51
-0% -$3.11K ﹤0.01% 1501
2021
Q3
$8.33M Sell
118,025
-2,292
-2% -$145K ﹤0.01% 1335
2021
Q2
$8.02M Buy
120,317
+34,371
+40% +$2.43M ﹤0.01% 1346
2021
Q1
$9.54M Buy
85,946
+935
+1% +$116K ﹤0.01% 1228
2020
Q4
$10.1M Sell
85,011
-1,389
-2% -$150K ﹤0.01% 1129
2020
Q3
$7.54M Sell
86,400
-12,370
-13% -$1.08M ﹤0.01% 1139
2020
Q2
$8.85M Sell
98,770
-86,250
-47% -$8.71M 0.01% 1052
2020
Q1
$18.4M Buy
185,020
+31,970
+21% +$3.47M 0.01% 709
2019
Q4
$17.6M Sell
153,050
-16,360
-10% -$1.98M 0.01% 858
2019
Q3
$21.4M Sell
169,410
-7,080
-4% -$899K 0.01% 763
2019
Q2
$21.2M Sell
176,490
-300
-0.2% -$29.5K 0.01% 785
2019
Q1
$15.5M Sell
176,790
-4,740
-3% -$431K 0.01% 878
2018
Q4
$18.2M Buy
181,530
+57,910
+47% +$6.08M 0.01% 777
2018
Q3
$14.2M Sell
123,620
-4,560
-4% -$472K 0.01% 881
2018
Q2
$11.5M Buy
128,180
+8,410
+7% +$710K 0.01% 911
2018
Q1
$8.76M Buy
119,770
+39,164
+49% +$2.69M 0.01% 987
2017
Q4
$4.68M Buy
80,606
+216
+0.3% +$11.4K ﹤0.01% 1255
2017
Q3
$3.61M Hold
80,390
﹤0.01% 1422
2017
Q2
$3.17M Sell
80,390
-1,000
-1% -$41.1K ﹤0.01% 1504
2017
Q1
$3.3M Sell
81,390
-11
-0% -$430 ﹤0.01% 1449
2016
Q4
$3.27M Hold
81,401
﹤0.01% 1479
2016
Q3
$2.95M Buy
81,401
+11
+0% +$378 ﹤0.01% 1490
2016
Q2
$2.36M Buy
81,390
+5,400
+7% +$163K ﹤0.01% 1564
2016
Q1
$2.66M Buy
75,990
+2,350
+3% +$75.9K ﹤0.01% 1392
2015
Q4
$2.37M Sell
73,640
-26,891
-27% -$872K ﹤0.01% 1473
2015
Q3
$3.25M Sell
100,531
-69
-0.1% -$2.6K ﹤0.01% 1286
2015
Q2
$4.16M Sell
100,600
-8,700
-8% -$367K ﹤0.01% 1214
2015
Q1
$4.91M Hold
109,300
﹤0.01% 1131
2014
Q4
$4.09M Sell
109,300
-2,600
-2% -$95.2K ﹤0.01% 1230
2014
Q3
$3.91M Hold
111,900
﹤0.01% 1219
2014
Q2
$3.95M Sell
111,900
-3,385
-3% -$113K ﹤0.01% 1272
2014
Q1
$3.76M Buy
115,285
+2,585
+2% +$98.8K ﹤0.01% 1292
2013
Q4
$4.75M Sell
112,700
-6,800
-6% -$280K ﹤0.01% 1139
2013
Q3
$4.77M Hold
119,500
﹤0.01% 1094
2013
Q2
$4.94M Buy
+119,500
New +$4.84M 0.01% 1013

Other funds holding HAE

AllianceBernstein's HAE Position: Q1 2026 in Review

AllianceBernstein increased its Haemonetics (HAE) stake by 0.51% in Q1 2026, buying an estimated $30.3K and bringing the position to 92,135 shares worth $7.38M. The position accounts for ﹤0.01% of the portfolio, ranked #1358.

AllianceBernstein first reported a position in HAE in Q2 2013 and has held it in 52 quarters since. The position peaked at $21.4M in Q3 2019. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.

  • AllianceBernstein held 92,135 shares of Haemonetics worth $7.38M as of Q1 2026.
  • AllianceBernstein bought 465 Haemonetics shares in Q1 2026, an estimated $30.3K.
  • Haemonetics made up ﹤0.01% of AllianceBernstein's portfolio in Q1 2026, its #1358 holding.
  • AllianceBernstein first reported a position in Haemonetics in Q2 2013 and has held it in 52 quarters since.
  • AllianceBernstein's Haemonetics position peaked at $21.4M in Q3 2019.
  • 324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.

Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.